Wall Street Analyst Initiated Sutro Biopharma Inc. [STRO]. What else is Wall St. saying

Sutro Biopharma Inc. [NASDAQ: STRO] surged by $0.9 during the normal trading session on Tuesday and reaching a high of $5.72 during the day while it closed the day at $5.23. The company report on June 27, 2022 that Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs).

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


– iADCs are a next-generation modality for treating cancer and designed to boost anti-cancer activity, offering potential new options for patients who do not respond to existing cancer immunotherapies -.

– Sutro will receive an upfront payment of US$90 million to develop iADCs for three biological targets and may be eligible to receive up to an additional US$422.5 million USD in development, regulatory and commercial milestones for each product candidate, plus royalties -.

Sutro Biopharma Inc. stock has also gained 33.42% of its value over the past 7 days. However, STRO stock has declined by -36.91% in the 3 months of the year. Over the past six months meanwhile, it has lost -64.10% and lost -64.85% year-on date.

The market cap for STRO stock reached $244.29 million, with 46.50 million shares outstanding and 41.56 million shares in the current float. Compared to the average trading volume of 641.21K shares, STRO reached a trading volume of 16966072 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Sutro Biopharma Inc. [STRO]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for STRO shares is $26.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on STRO stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

H.C. Wainwright have made an estimate for Sutro Biopharma Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 18, 2021. While these analysts kept the previous recommendation, Stifel raised their target price to Buy. The new note on the price target was released on December 03, 2020, representing the official price target for Sutro Biopharma Inc. stock. Previously, the target price had yet another raise to $21, while Jefferies analysts kept a Buy rating on STRO stock.

The Average True Range (ATR) for Sutro Biopharma Inc. is set at 0.44, with the Price to Sales ratio for STRO stock in the period of the last 12 months amounting to 4.60. The Price to Book ratio for the last quarter was 1.10, with the Price to Cash per share for the same quarter was set at 4.48.

STRO stock trade performance evaluation

Sutro Biopharma Inc. [STRO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 33.42. With this latest performance, STRO shares gained by 19.41% in over the last four-week period, additionally sinking by -64.10% over the last 6 months – not to mention a drop of -72.85% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for STRO stock in for the last two-week period is set at 61.77, with the RSI for the last a single of trading hit 72.59, and the three-weeks RSI is set at 54.23 for Sutro Biopharma Inc. [STRO]. The present Moving Average for the last 50 days of trading for this stock 5.07, while it was recorded at 4.45 for the last single week of trading, and 11.72 for the last 200 days.

Sutro Biopharma Inc. [STRO]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Sutro Biopharma Inc. [STRO] shares currently have an operating margin of -159.22 and a Gross Margin at +84.21. Sutro Biopharma Inc.’s Net Margin is presently recorded at -170.55.

Return on Equity for this stock declined to -36.11, with Return on Assets sitting at -28.70.

Sutro Biopharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.90 and a Current Ratio set at 5.90.

Sutro Biopharma Inc. [STRO]: Insider Ownership positions

There are presently around $181 million, or 91.80% of STRO stock, in the hands of institutional investors. The top three institutional holders of STRO stocks are: FRANKLIN RESOURCES INC with ownership of 3,747,914, which is approximately 14.687% of the company’s market cap and around 0.80% of the total institutional ownership; SUVRETTA CAPITAL MANAGEMENT, LLC, holding 3,732,400 shares of the stock with an approximate value of $16.16 million in STRO stocks shares; and BLACKROCK INC., currently with $16.15 million in STRO stock with ownership of nearly 0.778% of the company’s market capitalization.

Positions in Sutro Biopharma Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 63 institutional holders increased their position in Sutro Biopharma Inc. [NASDAQ:STRO] by around 10,964,146 shares. Additionally, 64 investors decreased positions by around 9,149,635 shares, while 15 investors held positions by with 21,634,289 shares. The mentioned changes placed institutional holdings at 41,748,070 shares, according to the latest SEC report filing. STRO stock had 23 new institutional investments in for a total of 3,654,675 shares, while 29 institutional investors sold positions of 6,345,961 shares during the same period.


Please enter your comment!
Please enter your name here